Literature DB >> 20653490

Novel combination therapy for the eradication of Helicobacter pylori infection in a mouse model.

Cuong D Tran1, Stamatiki Kritas, Mary A F Campbell, Hien Q Huynh, Su-San Lee, Ross N Butler.   

Abstract

OBJECTIVE: To investigate the combination therapy, consisting of hyperimmune bovine colostrum, N-acetyl cysteine, zinc and amoxicillin on the eradication of Helicobacter pylori in a mouse model.
MATERIAL AND METHODS: C57BL/6 female mice (6 weeks of age) were inoculated with 0.1 ml of 1×10(9) H. pylori via a single oro-gastric gavage and were left infected for 4 weeks. Mice (n=9/group) were randomly allocated to receive by oral gavage (0.1 ml) HNZ (hyperimmune bovine colostrum+N-acetyl cysteine+zinc), HNZA (HNZ+amoxicillin; A), HNZA2 (2× amoxicillin; A2), HNZA5 (5× amoxicillin; A5), triple therapy (TT) or saline twice daily for 10 days. Bacterial load was assessed by culture. Gastric emptying was assessed by 13C-octanoic acid breath test.
RESULTS: Mice receiving HNZ, HNZA, and HNZA2 have a 22%, 44% and 67% eradication rate, respectively. Eradication rate was 100% with HNZA5, TT and those animals receiving A5 alone. In H. pylori infected mice there was an increased gastric emptying time by 7.9, 3.7, 10.1 and 7.7 min for the TT, HNZ, HNZA2, and HNZA5, respectively, compared to saline.
CONCLUSIONS: HNZ with the addition of a high dose of amoxicillin is effective at eradicating H. pylori in vivo as HNZA1 and HNZA2 did not give raise to eradication. The potency of the novel anti-H. pylori combination therapy may be due to the delayed gastric emptying.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653490     DOI: 10.3109/00365521.2010.506245

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  N-acetyl cysteine as an adjunct to standard anti-Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open-label trial.

Authors:  Mohammad Hassan Emami; Mehdi Zobeiri; Hojatolah Rahimi; Fariba Arjomandi; Hamed Daghagzadeh; Peyman Adibi; Jalal Hashemi
Journal:  Adv Biomed Res       Date:  2014-09-08

2.  Carvacrol codrugs: a new approach in the antimicrobial plan.

Authors:  Ivana Cacciatore; Mara Di Giulio; Erika Fornasari; Antonio Di Stefano; Laura Serafina Cerasa; Lisa Marinelli; Hasan Turkez; Emanuela Di Campli; Soraya Di Bartolomeo; Iole Robuffo; Luigina Cellini
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

3.  N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions.

Authors:  Eduardo P Amaral; Elisabete L Conceição; Diego L Costa; Michael S Rocha; Jamocyr M Marinho; Marcelo Cordeiro-Santos; Maria Regina D'Império-Lima; Theolis Barbosa; Alan Sher; Bruno B Andrade
Journal:  BMC Microbiol       Date:  2016-10-28       Impact factor: 3.605

4.  Micromotor-enabled active drug delivery for in vivo treatment of stomach infection.

Authors:  Berta Esteban-Fernández de Ávila; Pavimol Angsantikul; Jinxing Li; Miguel Angel Lopez-Ramirez; Doris E Ramírez-Herrera; Soracha Thamphiwatana; Chuanrui Chen; Jorge Delezuk; Richard Samakapiruk; Valentin Ramez; Marygorret Obonyo; Liangfang Zhang; Joseph Wang
Journal:  Nat Commun       Date:  2017-08-16       Impact factor: 14.919

5.  Mucolytics as Adjuvant Agent to Improve Helicobacter pylori Eradication Rate: Still Long and Winding Road to Positive Results.

Authors:  Hyuk Yoon; Dong Ho Lee
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

6.  Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.

Authors:  Hyuk Yoon; Dong Ho Lee; Eun Sun Jang; Jaihwan Kim; Cheol Min Shin; Young Soo Park; Jin-Hyeok Hwang; Jin-Wook Kim; Sook-Hayng Jeong; Nayoung Kim
Journal:  Gut Liver       Date:  2016-07-15       Impact factor: 4.519

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.